Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 102

Get the latest international news and world events from around the world.

Log in for authorized contributors

Tesla’s Monster Week: $29B + Robotaxi Boom

Tesla is poised for significant growth and expansion, driven by advancements in its Full Self-Driving technology, robotaxi initiatives, and strategic partnerships, which could lead to a major increase in its stock value ## ## Questions to inspire discussion.

Tesla’s FSD and Robotaxi Advancements.

🚗 Q: What major update is coming to Tesla’s Full Self-Driving (FSD) system? A: A new FSD model with 10x more parameters is expected to be ready for public release by the end of next month, offering a big leap forward in capabilities.

🛣️ Q: How much safer is Tesla’s FSD compared to human drivers? A: Tesla’s FSD is reported to be 10x safer than human drivers, with the new model expected to provide a magnitude increase in safety and features.

🚕 Q: How is Tesla’s Robotaxi service expanding? A: Tesla’s Robotaxi service is expanding rapidly, with the geofenced area in Austin quadrupled to 80 square miles in just 42 days, and ride-hailing launched in California.

Tesla’s Strategic Moves.

Continue reading “Tesla’s Monster Week: B + Robotaxi Boom” | >

Study shows people overestimate hill steepness based on their eye level

People’s perceptions of the world are easily impacted by the angle at which they view objects in it, suggests a new study.

This finding, made by researchers from The Ohio State University, was revealed by testing people’s ability to estimate the steepness of a hill. The study, recently published in the journal Perception, showed that most people, regardless of their visual orientation — or line of sight — will consistently overestimate its steepness.

Dennis Shaffer, lead author of the study and a professor of psychology at The Ohio State University’s Mansfield campus, said his team’s research aimed to understand why this may be, as well as how manipulating a person’s gaze might result in notable differences in their perception.

Frustrated by Design: Chemistry Triggers Exotic Electron Behavior in New Quantum Material

In a striking demonstration of how chemical bonding can engineer exotic physics, researchers at Columbia University have discovered that quantum frustration —a key ingredient for superconductivity and other correlated quantum phases—can be induced not just by geometry, but directly through chemistry. The new material, Pd5AlI2, showcases this unusual electron behavior in a two-dimensional crystal structure with orbital configurations that mimic flat-band lattice geometries.

🔗 Original article on Phys.org

Organic molecule achieves both strong light emission and absorption for displays and imaging

Researchers at Kyushu University have developed a novel organic molecule that simultaneously exhibits two highly sought-after properties: efficient light emission suitable for advanced displays and strong light absorption for deep-tissue bioimaging. This breakthrough addresses a long-standing challenge in molecular design, paving the way for next-generation multifunctional materials.

Their study, published online in the journal Advanced Materials on July 29, 2025, was conducted in collaboration with the National Taipei University of Technology and the National Central University.

Organic light-emitting diodes (OLEDs) are at the forefront of modern display and lighting technologies, powering nearly everything from smartphone screens to large televisions and monitors. A key phenomenon that is actively being researched to enhance OLED efficiency is thermally activated delayed fluorescence (TADF).

Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy

Clinical validation of stem cell reactivation approach positions Pelage as leader in regenerative medicine and aging

LOS ANGELES—(BUSINESS WIRE)— #HairLoss —Pelage Pharmaceuticals, a clinical-stage regenerative medicine company, today announced positive results from its Phase 2a clinical trial of PP405 — a topical therapy for androgenetic alopecia advancing through the FDA clinical development pathway. PP405 is designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class approach for both men and women experiencing hair loss.

/* */